RxDoctor Payments Data

Candise Love

Acute Care · Port Huron, MINPI 1801102371

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,488 of the $14,464 with a category attached, or 86.3%. It is spread thinly across 60 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,178, 2.2 times the $1,936 reported in 2021. Among acute care clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,464in general payments, 2019–2025

Across 619 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • Merck$876
  • AbbVie$765
  • Daiichi Sankyo Inc.$534
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,48886%
  • Education$7966%
  • Other$1,1808%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis79$2,396
AstraZeneca(2 entities)45$1,020
Johnson & Johnson53$1,018
Merck35$876
AbbVie23$765
Daiichi Sankyo Inc.25$534
Eisai Inc.28$533
Incyte Corporation20$463
Lilly USA, LLC25$440
Genentech USA, Inc.22$402
Gilead(2 entities)15$348
Takeda Pharmaceuticals U.S.A., Inc.11$345
Sanofi13$294
Astellas Pharma US Inc14$289
Amgen11$235
GSK12$232
Sobi, Inc9$225
Seagen Inc.13$224
E.r. Squibb & Sons, L.L.C.6$220
Exelixis Inc.6$178
AMAG Pharmaceuticals, Inc.9$172
Ipsen Biopharmaceuticals, Inc7$170
EMD Serono, Inc.2$165
ASD Specialty Healthcare, LLC3$164
AVEO Pharmaceuticals, Inc.10$163
Beigene USA, Inc.7$151
Bristol Myers Squibb9$142
Geron Corporation3$137
Servier Pharmaceuticals LLC8$136
Mirati Therapeutics, Inc.7$131
Pfizer6$118
Pharmacyclics LLC, An Abbvie Company7$109
Avyxa Pharma, LLC1$103
Karyopharm Therapeutics Inc.4$102
Deciphera Pharmaceuticals Inc.6$99
Bayer6$91
Genmab U.S., Inc.4$86
Eagle Pharmaceuticals, Inc.2$75
Agios Pharmaceuticals, Inc.3$72
Pharmacosmos Therapeutics Inc.4$71
Apellis Pharmaceuticals, Inc.3$70
Acrotech Biopharma Inc.2$65
Regeneron Healthcare Solutions, Inc.2$64
Sumitomo Pharma America, Inc.3$62
Janssen Scientific Affairs, LLC2$59
Myriad Genetic Laboratories, Inc.3$55
Macrogenics, Inc.2$49
Fresenius Kabi USA, LLC2$45
Stemline Therapeutics Inc.2$45
Azurity Pharmaceuticals, Inc.2$43
Pharmaessentia USA Corporation2$43
Array Biopharma Inc2$40
Taiho Oncology, Inc.2$38
Puma Biotechnology, Inc.2$33
Tactile Systems Technology Inc2$33
Dova Pharmaceuticals2$31
Morphosys, US Inc.2$27
Recordati_rare_diseases_inc.1$26
Rigel Pharmaceuticals, Inc.1$21
Immunogen, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,464 in reported general payments places this provider in the 95th percentile of 567 acute care providers in Michigan.

See all acute care providers in Michigan

Medicare billing

Part B allowed, 2024
$15,378
Medicare patients
96
Services billed
709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$26,893
XareltoRivaroxaban11$5,893
Aprepitant19$5,700
Ondansetron OdtOndansetron59$1,525
Megestrol Acetate13$1,102
Dexamethasone23$626
Hydrocortisone15$570
Hydroxyurea17$449
Acyclovir32$409
Nystatin14$344
Olanzapine27$302
Ondansetron Hcl43$285
Prednisone37$245
Lidocaine-PrilocaineLidocaine/Prilocaine14$143
Pantoprazole Sodium11$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$118$26,89339 claims
Johnson & JohnsonXarelto$1,018$5,89311 claims
Lilly USA, LLCOlanzapine$440$30227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 acute care providers in Michigan.

Other acute care in Port Huron

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →